Clinical Trial to Evaluate ANT-1403 in the Treatment of Primary Axillary Hyperhidrosis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01799824 |
Recruitment Status :
Completed
First Posted : February 27, 2013
Last Update Posted : December 10, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Primary Axillary Hyperhidrosis | Biological: ANT-1403 Biological: placebo | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 52 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Clinical Trial to Evaluate ANT-1403 in the Treatment of Primary Axillary Hyperhidrosis in Adults |
Study Start Date : | February 2013 |
Actual Primary Completion Date : | July 2013 |
Actual Study Completion Date : | July 2013 |
Arm | Intervention/treatment |
---|---|
Experimental: Active
ANT-1403
|
Biological: ANT-1403 |
Placebo Comparator: Vehicle
Vehicle
|
Biological: placebo |
- HDSS [ Time Frame: Week 8 ]
- GSP [ Time Frame: Week 8 ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- ages 18 - 70 years of age
- diagnosis of moderate to severe primary axillary hyperhidrosis
- ≥50 mg of sweat production/axilla in 5 minutes as measured gravimetrically
- HDSS score of ≥3
Exclusion Criteria:
- diagnosis of secondary hyperhidrosis
- skin affliction in the axilla requiring medical treatment
- 20% aluminum hydrochloride, e.g. Drysol®, in 2 weeks prior of Baseline
- oral anticholinergic treatment
- botulinum toxin treatment in the prior 9 months
- history of surgery for axillary hyperhidrosis
- present or history of neuromuscular disease
- female subjects who are pregnant or are nursing a child

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01799824
United States, Florida | |
Miami, Florida, United States, 33137 | |
Pinellas Park, Florida, United States, 33781 | |
West Palm Beach, Florida, United States, 33401 | |
United States, Kentucky | |
Louisville, Kentucky, United States, 40202 | |
United States, New Jersey | |
East Windsor, New Jersey, United States, 08520 | |
United States, New York | |
Rochester, New York, United States, 14623 | |
United States, North Carolina | |
Raleigh, North Carolina, United States, 27612 | |
United States, Pennsylvania | |
Yardley, Pennsylvania, United States, 19067 | |
United States, Virginia | |
Norfolk, Virginia, United States, 23507 |
Responsible Party: | Anterios Inc. |
ClinicalTrials.gov Identifier: | NCT01799824 |
Other Study ID Numbers: |
ANT-1403-HHID-202 |
First Posted: | February 27, 2013 Key Record Dates |
Last Update Posted: | December 10, 2013 |
Last Verified: | November 2013 |
Hyperhidrosis Sweat Gland Diseases Skin Diseases |